Actively Recruiting
Study to Evaluate Psilocybin Monitors in Psilocybin Therapy for Adults with Treatment-Resistant Depression
Led by Centre for Addiction and Mental Health · Updated on 2026-08-21
40
Participants Needed
2
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the role of psilocybin monitors in psilocybin therapy for adults with treatment-resistant depression. Psilocybin, the active component of magic mushrooms, has shown large and sustained antidepressant effects in previous trials when combined with psychological support. This pilot randomized clinical trial aims to clarify how monitoring affects the therapy outcomes in this patient group. Participants receive 25 mg of psilocybin combined with either safety monitoring PSM or psychedelic-assisted therapy PAT. The study compares these two approaches to understand their impact on treatment. The trial is randomized and quadruple-masked, involving parallel groups receiving different monitoring strategies alongside the psilocybin dose. During the study, participants undergo screening to confirm eligibility and safety, including blood tests. They must taper off certain medications before baseline visits. Caregivers assist participants during and after treatment sessions. The study measures feasibility, tolerability, and safety over 24 months, with assessments including clinical interviews and monitoring of adverse events. Participants are expected to comply with study procedures and lifestyle guidelines throughout the trial.
CONDITIONS
Brief Title
Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression
Research Team
E
Emily Gilbert, MSc
P
Psychedelics Research
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here